Celularity (CELU) News Today $3.14 +0.15 (+5.02%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 23, 2024 | americanbankingnews.comCritical Survey: TFF Pharmaceuticals (NASDAQ:TFFP) versus Celularity (NASDAQ:CELU)July 19, 2024 | finance.yahoo.comAmniotic Products Market Size to Hit US$ 1.67 Billion By 2032, Due to Rise in Patient Population & Surgical Interventions | Research by SNS InsiderJune 25, 2024 | marketbeat.comCelularity (NASDAQ:CELU) Trading 0.7% Higher Celularity (NASDAQ:CELU) Stock Price Up 0.7%June 3, 2024 | globenewswire.comCelularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2024 | marketbeat.comShort Interest in Celularity Inc. (NASDAQ:CELU) Rises By 5.4%Celularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 627,100 shares, a growth of 5.4% from the April 30th total of 595,000 shares. Currently, 5.9% of the shares of the company are short sold. Based on an average trading volume of 70,000 shares, the days-to-cover ratio is currently 9.0 days.May 24, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingMay 14, 2024 | globenewswire.comCelularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T TherapyMay 12, 2024 | marketbeat.comShort Interest in Celularity Inc. (NASDAQ:CELU) Grows By 51.4%Celularity Inc. (NASDAQ:CELU - Get Free Report) saw a large increase in short interest in April. As of April 30th, there was short interest totalling 595,000 shares, an increase of 51.4% from the April 15th total of 393,100 shares. Approximately 5.6% of the shares of the stock are sold short. Based on an average daily volume of 72,300 shares, the days-to-cover ratio is currently 8.2 days.April 22, 2024 | globenewswire.comCelularity Inc. to Host Investor and Analyst Research & Development DayApril 19, 2024 | globenewswire.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K FilingApril 18, 2024 | globenewswire.comCelularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024April 15, 2024 | globenewswire.comCelularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial ProductsApril 8, 2024 | globenewswire.comCelularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental CellsMarch 30, 2024 | marketbeat.comCelularity Inc. (NASDAQ:CELU) Short Interest Down 16.8% in MarchCelularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 388,300 shares, a decrease of 16.8% from the February 29th total of 466,600 shares. Based on an average trading volume of 269,900 shares, the short-interest ratio is currently 1.4 days. Approximately 3.7% of the shares of the stock are sold short.March 26, 2024 | finance.yahoo.comCelularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3LMarch 20, 2024 | finanznachrichten.deCelularity Inc.: Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 20, 2024 | markets.businessinsider.comCelularity Announces Submission Of Request For Orphan Drug Designation For PDA-002March 20, 2024 | globenewswire.comCelularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular DystrophyMarch 16, 2024 | finance.yahoo.comCELU Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comCELU Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comCelularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 14, 2024 | globenewswire.comCelularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE SummitMarch 12, 2024 | marketbeat.comCelularity Inc. (NASDAQ:CELU) Short Interest Down 87.6% in FebruaryCelularity Inc. (NASDAQ:CELU - Get Free Report) was the recipient of a significant drop in short interest in February. As of February 29th, there was short interest totalling 466,600 shares, a drop of 87.6% from the February 14th total of 3,750,000 shares. Currently, 4.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 264,800 shares, the short-interest ratio is currently 1.8 days.March 12, 2024 | globenewswire.comCelularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World CongressMarch 8, 2024 | edition.cnn.comCelularity Inc. Class AMarch 7, 2024 | globenewswire.comCelularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental CellsFebruary 29, 2024 | marketbeat.comTrading was temporarily halted for "CELU" at 07:02 PM with a stated reason of "News pending."February 24, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Announces 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comStocks to Watch: Intuitive Machines, CelularityFebruary 23, 2024 | markets.businessinsider.comCelularity Announce 1-for-10 Reverse Stock SplitFebruary 23, 2024 | marketwatch.comCelularity to Effect 1-for-10 Reverse Stock SplitFebruary 23, 2024 | globenewswire.comCelularity Announces 1-for-10 Reverse Stock SplitFebruary 22, 2024 | finance.yahoo.comCelularity Inc.'s (NASDAQ:CELU) top owners are public companies with 35% stake, while 35% is held by individual investorsFebruary 14, 2024 | finance.yahoo.comCelularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface DiseaseFebruary 14, 2024 | globenewswire.comCelularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface DiseaseFebruary 6, 2024 | benzinga.comCelularity Stock (NASDAQ:CELU) Dividends: History, Yield and DatesFebruary 1, 2024 | finance.yahoo.comCelularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development PipelineJanuary 25, 2024 | finance.yahoo.comCelularity and Genting Leaders Comments on Closing $21 Million Financing TransactionsJanuary 19, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Releases CEO Letter to ShareholdersJanuary 18, 2024 | marketwatch.comCelularity CEO Says 2023 Revenue to Rise About 23% to 27%January 18, 2024 | finance.yahoo.comCelularity Releases CEO Letter to ShareholdersJanuary 4, 2024 | marketwatch.comCelularity Gets Commercialization Deal For Oral Healthcare ProductsJanuary 4, 2024 | finance.yahoo.comCelularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral HealthcareJanuary 3, 2024 | finanznachrichten.deCelularity, Inc.: Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023January 3, 2024 | marketwatch.comCelularity Expects 4Q Product, Services Sales to Nearly TripleJanuary 3, 2024 | msn.comCelularity announces fourth-quarter full-year 2023 revenue outlookJanuary 3, 2024 | finance.yahoo.comCelularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023December 2, 2023 | finance.yahoo.comCelularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingNovember 27, 2023 | finanznachrichten.deCelularity, Inc.: Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q FilingNovember 24, 2023 | msn.comCelularity announces receipt of Nasdaq notice regarding late Form 10-Q filing Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address How to build the ultimate dividend portfolio (Ad)There’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps? PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE… This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again. Click here and I’ll show you how to build the ultimate dividend portfolio. CELU Media Mentions By Week CELU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CELU News Sentiment▼0.630.62▲Average Medical News Sentiment CELU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CELU Articles This Week▼21▲CELU Articles Average Week Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ATIP News Today CMAX News Today MVST News Today STTK News Today ABOS News Today GBIO News Today VTYX News Today GTHX News Today XBIT News Today CHRS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CELU) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.